Mantle Cell Lymphoma - 23 Studies Found
| RECRUITING |
: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients : Mantle Cell Lymphoma : 2024-11-23 : Given by PO |
| COMPLETED |
: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2024-11-23 : The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do |
| COMPLETED |
: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2024-11-23 : Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, |